The company is hoping for early approval for the trails of the intranasal COVID-19 booster given the fast spread of the Omicron variant, denoted as B.1.1.529.īharat Biotech is the second company to submit an application for phase 3 clinical trial for the third dose in India.Įxplaining the need for a booster dose, Dr Dhiren Gupta, Senior Paediatrician at Sir Ganga Ram Hospital said, "This may have some protective value. ![]() Intranasal vaccines have the potential to prevent against transmission."Īccording to sources, the application was submitted by Bharat Biotech on December 15 for its booster dose of their intranasal COVID-19 vaccine that can be given to Covaxin and Covishield vaccinated people. An intranasal vaccine as a booster dose will be easier to administer in mass vaccination campaigns. Sources told ANI that Bharat Biotech in an application has said, "We have submitted phase 3 clinical trial application to DCGI. New Delhi, December 20 (ANI): As India is witnessing a surge in cases of "highly transmissible" Omicron variant, Hyderabad-based Bharat Biotech has submitted the phase 3 clinical trial application to the Drugs Controller General of India ( DCGI) to get approval for the booster dose of their intranasal COVID-19 vaccine named 'BBV154', as per sources.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |